Возможности лучевой терапии в контроле регионарного прогрессирования при раннем раке молочной железы

   Общепринятым стандартом в хирургии раннего рака молочной железы (РМЖ) в настоящее время является органосохраняющая операция с последующей дистанционной лучевой терапией и системной терапией. Согласно результатам исследований, органосохраняющие операции имеют преимущество по показателям общей выживаемости и уровню локального контроля. До настоящего времени предметом активной дискуссии остается ряд вопросов, связанных с методологией облучения пациенток с РМЖ. Целесообразно ли облучение аксиллярной зоны после радикальной резекции по поводу раннего РМЖ? Обеспечивает ли облучение аксиллярных лимфатических узлов сопоставимый с лимфодиссекцией регионарный контроль и может ли быть альтернативой лимфодиссекции у больных ранним РМЖ без клинических признаков регионарных метастазов (N0)? Обеспечивает ли облучение аксиллярных лимфатических узлов сопоставимый с лимфодиссекцией регионарный контроль у больных с метастазами в сторожевые лимфатические узлы? К настоящему времени опубликовано множество исследований, содержащих ответы на эти вопросы, основные из которых мы приводим в данной работе.

1. Актуальные аспекты клинической маммологии. Под ред. Е. Б. Камповой-Полевой и С. М. Портного. М.: Авторская Академия, 2014. C. 12–17.

2. Siegel R. L., Miller K. D., Fuchs H. E., Jemal A. Cancer statistics, 2022. Cancer J Clin 2022; 72: 7–33. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.3322/caac.21708.

3. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 249 с.

4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 4. 2022, June 21, 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

5. Curigliano G., Burstein H. J., Winer E. P. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28 (8): 1700–12. DOI: 10.1093/annonc/mdx308. Erratum in: Ann Oncol 2018; 29 (10): 2153.

6. Antonini N., Jones H., Horiot J.C. et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007; 82 (3): 265–71. DOI: 10.1016/j.radonc.2006.09.014

7. Clarke M., Collins R., Darby S. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366 (9503): 2087–106. DOI: 10.1016/S0140-6736(05)67887-7

8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S., McGale P. et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804): 1707–16. DOI: 10.1016/S0140-6736(11)61629-2

9. Fisher B., Anderson S., Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347 (16): 1233–41. DOI: 10.1056/NEJMoa022152

10. Fisher B., Bryant J., Dignam J. J. et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20 (20): 4141–9. DOI: 10.1200/JCO.2002.11.101

11. Van Nes J. G., van de Velde C. J. The preferred treatment for young women with breast cancer – mastectomy versus breast conservation. Breast 2006; 15 (Suppl 2): S3–10. DOI: 10.1016/S0960-9776(07)70009-7. Erratum in: Breast 2008; 17 (2): 213.

12. Veronesi U., Cascinelli N., Mariani L. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347 (16): 1227–32. DOI: 10.1056/NEJMoa020989

13. Yarnold J., Ashton A., Bliss J. et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005; 75 (1): 9–17. DOI: 10.1016/j.radonc.2005.01.005

14. Corradini S., Reitz D., Pazos M. et al. Mastectomy or breast-conserving therapy for early breast cancer in real-life clinical practice: outcome comparison of 7565 cases. Cancers (Basel) 2019; 11 (2): 160. DOI: 10.3390/cancers11020160

15. Van Maaren M. C., de Munck L., de Bock G. H. et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol 2016; 17 (8): 1158–70. DOI: 10.1016/S1470-2045(16)30067-5

16. Christiansen P., Carstensen S. L., Ejlertsen B. et al. Breast conserving surgery versus mastectomy: overall and relative survival – a population based study by the Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol 2018; 57 (1): 19–25. DOI: 10.1080/0284186X.2017.1403042

17. Hartmann-Johnsen O. J., Kåresen R., Schlichting E., Nygård J. F. Survival is better after breast conserving therapy than mastectomy for early stage breast cancer: a registry-based follow-up study of Norwegian women primary operated between 1998 and 2008. Ann Surg Oncol 2015; 22 (12): 3836–45. DOI: 10.1245/s10434-015-4441-3

18. Fisher S., Gao H., Yasui Y. et al. Survival in stage I–III breast cancer patients by surgical treatment in a publicly funded health care system. Ann Oncol 2015; 26 (6): 1161–9. DOI: 10.1093/annonc/mdv107

19. Hofvind S., Holen Å., Aas T. et al. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol 2015; 41 (10): 1417–22. DOI: 10.1016/j.ejso.2015.07.002

20. Onitilo A. A., Engel J. M., Stankowski R. V., Doi S. A. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. Clin Med Res 2015; 13 (2): 65–73. DOI: 10.3121/cmr.2014.1245

21. Chen K., Liu J., Zhu L. et al. Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: a NCDB analysis. Oncotarget 2015; 6 (37): 40127–40. DOI: 10.18632/oncotarget.5394

22. Wang X., Gao Y., Yang X. et al. Omitting ALND is not safe for a cohort of early-stage breast cancer patients with 1–2 SLNs macro-metastases and breast-conserving therapy: a single-center retrospective study. Iran J Public Health 2020; 49 (7): 1262–8. DOI: 10.18502/ijph.v49i7.3579

23. Donker M., Rutgers E. J. T., van de Velde C. J. et al. Axillary lymph node dissection versus axillary radiotherapy: A detailed analysis of morbidity. Results from EORTC 10981-22023 AMAROS trial. Eur J Cancer 2013; 49: 14.

24. Haffty B. G., McCall L. M., Ballman K. V. et al. Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys 2016; 94 (3): 493–502. DOI: 10.1016/j.ijrobp.2015.11.005

25. Jagsi R., Chadha M., Moni J. et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol 2014; 32 (32): 3600–6. DOI: 10.1200/JCO.2014.56.5838

26. Louis-Sylvestre C., Clough K., Asselain B. et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 2004; 22 (1): 97–101. DOI: 10.1200/JCO.2004.12.108

27. Fisher B., Jeong J. H., Anderson S. et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347 (8): 567–75. DOI: 10.1056/NEJMoa020128

28. Giuliano A. E., Hunt K. K., Ballman K. V. et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305 (6): 569–75. DOI: 10.1001/jama.2011.90

29. Galimberti V., Cole B. F., Zurrida S. et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14 (4): 297–305. DOI: 10.1016/S1470-2045(13)70035-4. Erratum in: Lancet Oncol 2013; 14 (7): e254.

30. Louis-Sylvestre C., Clough K., Asselain B. et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 2004; 22 (1): 97–101. DOI: 10.1200/JCO.2004.12.108

31. Whelan T. J., Olivotto I. A., Parulekar W. R. et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015; 373 (4): 307–16. DOI: 10.1056/NEJMoa1415340

32. Donker M., van Tienhoven G., Straver M. E. et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15 (12): 1303–10. DOI: 10.1016/S1470-2045(14)70460-7

33. Landin J., Weber W. P. Lymph node surgery – stepwise retirement for the breast surgeon? Breast Care (Basel) 2016; 11 (4): 282–6. DOI: 10.1159/000448697

34. Giuliano A. E., Ballman K. V., McCall L. et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017; 318 (10): 918–26. DOI: 10.1001/jama.2017.11470

35. Giuliano A. E., McCall L., Beitsch P. et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252 (3): 426–32; discussion 432–3. DOI: 10.1097/SLA.0b013e3181f08f32